YPI 009
Alternative Names: YPI-009Latest Information Update: 05 Feb 2021
At a glance
- Originator Yungjin Pharm Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 19 Jan 2021 Preclinical trials in Unspecified in South Korea (unspecified route) (Yungjin Pharma pipeline, January 2021)